Traphaco Joint Stock Company Sustainability Profile
Traphaco Joint Stock Company, commonly referred to as Traphaco, is a leading pharmaceutical enterprise headquartered in Vietnam. Established in 1972, the company has made significant strides in the healthcare sector, particularly in the production and distribution of herbal medicines and dietary supplements. With a strong operational presence across major regions in Vietnam, Traphaco is renowned for its commitment to quality and innovation. The company’s core offerings include a diverse range of herbal products, pharmaceuticals, and functional foods, distinguished by their adherence to traditional medicine principles combined with modern scientific research. Traphaco has achieved notable recognition in the market, positioning itself as a trusted brand in the Vietnamese pharmaceutical industry. Its dedication to sustainable practices and community health further solidifies its reputation as a pioneer in the sector.
DitchCarbon Score
How does Traphaco Joint Stock Company's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Traphaco Joint Stock Company's score of 22 is lower than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Traphaco Joint Stock Company's reported carbon emissions
Traphaco Joint Stock Company, headquartered in Vietnam, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges from the company. As a result, Traphaco's climate commitments and initiatives remain unclear, and there is no inherited emissions data from a parent or related organization. The company may be in the early stages of developing its climate strategy or reporting framework. In the context of the pharmaceutical industry, companies are increasingly focusing on sustainability and carbon reduction, often setting science-based targets to align with global climate goals. However, without specific data or commitments from Traphaco, it is challenging to assess their position within this evolving landscape.
How Carbon Intensive is Traphaco Joint Stock Company's Industry?
How Carbon Intensive is Traphaco Joint Stock Company's Location?
Traphaco Joint Stock Company's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Traphaco Joint Stock Company has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
